------------------------------------------------------------- Stay up to date with everything obesity through my newsletter To view or add a comment, sign in Late-phase clinical trial news Eli Lillys oral GLP-1 therapy orforglipron met all primary and secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 trials, showing significant A1C reduction, weight loss, and cardiovascular improvements versus dapagliflozin and placebo
Rosenstock J, Raccah D, Koranyi L, Maffei L, Boka G, Miossec P, et al
Inconsistent timing undermines protocol effectiveness
Additionally, track essential health metrics such as weight, calorie intake, protein consumption, and water intake to gain a holistic view of your health journey